A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inaticabtagene autoleucel (Primary)
Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
16 Sep 2019 According to a CASI Pharmaceuticals media release, the Chinese National Medical Product Administration (NMPA), the Chinese FDA, has accepted the clinical trial application for CNCT19 (CD19 CAR-T) for investigation in relapsed B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).
21 Jun 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com